THU0481-HPR Lessons from patient reported outcomes of biologic treatment: Improvements in quality of life and health status are stable over time despite declining physical function. (23rd January 2014)

• Record Type: Journal Article
• Authors: Harrison, T.; Barnabe, C.; Martin, L.; Barr, S.G.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 741
• Page End: 741
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.2446
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patient reported outcomes are an important aspect of outcome evaluation, and supplement the argument for the necessity of these therapies. Objectives: To evaluate improvements in RA treated biologic patients' reported function, quality of life and health status over the course of treatment. Methods: The Alberta Biologics Pharmacosurveillance Program captures the clinical efficacy and safety of biologic therapies in RA since 2000. HAQ scores, SF-36 and the EQ-5D are completed every six months. Results: Our cohort includes 605 patients (74% female, mean age 43 years). Mean disease activity at baseline was: DAS28 5.73, patient global score 6.8, TJC 4.4 and SJC 3.2. Improvement in the 8 domains of the SF-36 occurred over the first year of treatment and stabilized thereafter (Figure 1 ). A similar trend occurred in the 5 domains of the EQ-5D. HAQ scores showed improvement in the first year of therapy (mean baseline HAQ 1.59, HAQ at 1 year 0.76), followed by stabilization but began to rise again after 4 years (mean HAQ at 7 years 0.96). Conclusions: Health status and quality of life significantly improve with biologic therapy, with the most impressive benefit in the first year of therapy followed by a period of stabilization lasting over 11 years. The worsening of physical function after 4 years is not associated with deterioration in other domains, which is unexpected. Disclosure of Interest: None Declared